Sanz-Cánovas, JaimeLópez-Sampalo, AlmudenaCobos-Palacios, LidiaRicci, MicheleHernández-Negrín, HalbertMancebo-Sevilla, Juan JoséÁlvarez-Recio, ElenaLópez-Carmona, María DoloresPérez-Belmonte, Luis MiguelGómez-Huelgas, RicardoBernal-López, Maria Rosa2023-05-032023-05-032022-07-16http://hdl.handle.net/10668/21084The life expectancy of the population is increasing worldwide due to improvements in the prevention, diagnosis, and treatment of diseases. This favors a higher prevalence of type 2 diabetes mellitus (T2DM) in the elderly. Sarcopenia and frailty are also frequently present in aging. These three entities share common mechanisms such as insulin resistance, chronic inflammation, and mitochondrial dysfunction. The coexistence of these situations worsens the prognosis of elderly patients. In this paper, we review the main measures for the prevention and management of sarcopenia and/or frailty in elderly patients with T2DM.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/elderlyfrailtysarcopeniatype 2 diabetes mellitusAgedAgingDiabetes Mellitus, Type 2Frail ElderlyFrailtyHumansSarcopeniaresearch article35886528open access10.3390/ijerph191486771660-4601PMC9318510https://www.mdpi.com/1660-4601/19/14/8677/pdf?version=1658135236https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318510/pdf